Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSS | P25774 | 1/20 | 0.53 |
| ▸ | CTSK | P43235 | 1/20 | 0.53 |
| ▸ | NAMPT | P43490 | 9/20 | 0.40 |
| ▸ | GAA | P10253 | 2/20 | 0.37 |
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
| ▸ | PKM | P14618 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | KCNA5 | P22460 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4906749 | 0.85 | CTSK (0.58) | CTSSCTSKNAMPTGAATSHR | |
| SCHEMBL4904948 | 0.83 | CTSS (0.62) | CTSSCTSKNAMPTGAATSHR | |
| SCHEMBL4904956 | 0.83 | CTSS (0.62) | CTSSCTSKNAMPTGAATSHR | |
| SCHEMBL6647675 | 0.81 | KMT2A (0.49) | CTSKNAMPTGAAPKMKMT2A | |
| SCHEMBL14260245 | 0.75 | CTSK (0.78) | CTSSCTSKNAMPTGAATSHR | |
| SCHEMBL4908452 | 0.73 | CTSS (0.70) | CTSSCTSKNAMPTGAATSHR | |
| SCHEMBL4908456 | 0.73 | CTSS (0.70) | CTSSCTSKNAMPTGAATSHR | |
| SCHEMBL14260244 | 0.69 | CTSK (1.00) | CTSSCTSK | |
| SCHEMBL4904781 | 0.69 | CTSS (0.44) | CTSSCTSKNAMPTPKMKMT2A | |
| SCHEMBL4904759 | 0.69 | CTSS (0.44) | CTSSCTSKNAMPTPKMKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080058333-A1 | CYCLOALKYL KETOAMIDES DERIVATIVES USEFUL AS CATHEPSIN K INHIBITORS | CATALANO JOHN G | 2008-03-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080058333-A1 | CYCLOALKYL KETOAMIDES DERIVATIVES USEFUL AS CATHEPSIN K INHIBITORS | CTSK, CTSS, CTSE | CTSS 2/4885CTSK 1/4885NAMPT 1150/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.